Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Advisor OS LLC

Advisor OS LLC reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 1.4% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 15,102 shares of the medical research company’s stock after selling 216 shares during the quarter. Advisor OS LLC’s holdings in Edwards Lifesciences were worth $1,395,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Park Avenue Securities LLC increased its position in Edwards Lifesciences by 0.5% during the 2nd quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares in the last quarter. City State Bank increased its position in Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after purchasing an additional 130 shares in the last quarter. Chapin Davis Inc. increased its position in Edwards Lifesciences by 1.7% during the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after purchasing an additional 140 shares in the last quarter. Johnson Financial Group Inc. increased its position in Edwards Lifesciences by 23.0% during the 4th quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock worth $59,000 after purchasing an additional 144 shares in the last quarter. Finally, Valley National Advisers Inc. increased its position in Edwards Lifesciences by 6.0% during the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after purchasing an additional 152 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock valued at $1,321,988 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Oppenheimer dropped their target price on shares of Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating for the company in a research report on Thursday, July 25th. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $105.00 to $75.00 in a report on Thursday, July 25th. JPMorgan Chase & Co. cut Edwards Lifesciences from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $105.00 to $72.00 in a report on Thursday, July 25th. Finally, StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Fourteen research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $82.10.

Edwards Lifesciences Price Performance

Shares of EW opened at $66.81 on Friday. The firm has a market capitalization of $40.26 billion, a price-to-earnings ratio of 28.80, a price-to-earnings-growth ratio of 2.92 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock’s fifty day moving average is $74.75 and its 200-day moving average is $84.17.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. The company had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the company earned $0.66 earnings per share. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.